Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP617072.RAblkLaefgjouUmbvBtoC_BRjTtX9A9EzPtRHnXX0WB0k130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP617072.RAblkLaefgjouUmbvBtoC_BRjTtX9A9EzPtRHnXX0WB0k130_assertion type Assertion NP617072.RAblkLaefgjouUmbvBtoC_BRjTtX9A9EzPtRHnXX0WB0k130_head.
- NP617072.RAblkLaefgjouUmbvBtoC_BRjTtX9A9EzPtRHnXX0WB0k130_assertion description "[Since anti-PLGF was recently applied in clinical trials to inhibit cancer-related angiogenesis, here our data further demonstrate that inhibition of cancer neovascularization by anti-PLGF is mediated not only by direct effect on endothelial growth and capillary permeability, but also by indirect effect via MMP3 on the extracellular matrix degradation in larynx carcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP617072.RAblkLaefgjouUmbvBtoC_BRjTtX9A9EzPtRHnXX0WB0k130_provenance.
- NP617072.RAblkLaefgjouUmbvBtoC_BRjTtX9A9EzPtRHnXX0WB0k130_assertion evidence source_evidence_literature NP617072.RAblkLaefgjouUmbvBtoC_BRjTtX9A9EzPtRHnXX0WB0k130_provenance.
- NP617072.RAblkLaefgjouUmbvBtoC_BRjTtX9A9EzPtRHnXX0WB0k130_assertion SIO_000772 24946722 NP617072.RAblkLaefgjouUmbvBtoC_BRjTtX9A9EzPtRHnXX0WB0k130_provenance.
- NP617072.RAblkLaefgjouUmbvBtoC_BRjTtX9A9EzPtRHnXX0WB0k130_assertion wasDerivedFrom befree-20150227 NP617072.RAblkLaefgjouUmbvBtoC_BRjTtX9A9EzPtRHnXX0WB0k130_provenance.
- NP617072.RAblkLaefgjouUmbvBtoC_BRjTtX9A9EzPtRHnXX0WB0k130_assertion wasGeneratedBy ECO_0000203 NP617072.RAblkLaefgjouUmbvBtoC_BRjTtX9A9EzPtRHnXX0WB0k130_provenance.